These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32500455)

  • 41. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers.
    Greene M; Burudpakdee C; Seetasith A; Behling M; Krasa H
    Curr Med Res Opin; 2019 Jan; 35(1):97-103. PubMed ID: 30322282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparisons of the effects of second-generation antipsychotics long-acting injections on treatment retention according to severity of patient condition.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2018 Oct; 37():64-66. PubMed ID: 30144778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.
    Olivares JM; Fagiolini A
    Front Psychiatry; 2022; 13():877867. PubMed ID: 35573364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication.
    Campagna EJ; Muser E; Parks J; Morrato EH
    J Manag Care Spec Pharm; 2014 Jul; 20(7):756-66. PubMed ID: 24967528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment persistence with aripiprazole once monthly: a 4-year follow-up.
    Fagiolini A; Aguglia E; Ballerini A; Callista G; Carpiniello B; Clerici M; Corrivetti G; Cuomo A; De Fazio P; De Filippis S; De Giorgi S; Goracci A; La Barbera D; Mencacci C; Montagnani G; Pigato G; Vannucchi J; Vita A
    Ann Gen Psychiatry; 2022 Sep; 21(1):39. PubMed ID: 36175924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan.
    Wang H; Zhang Y; Liu J; Chi R; Wu T; Zhang T; Zhang L; Jiang K; Qiu H; Dong W; Si T
    J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34963203
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
    Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
    Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).
    Oluboka O; Clerzius G; Janetzky W; Schöttle D; Therrien F; Wiedemann K; Roy MA
    BMC Psychiatry; 2023 May; 23(1):383. PubMed ID: 37259053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):627-636. PubMed ID: 29694243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
    Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
    Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.
    Okada Y; Inada K; Akazawa M
    J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):263-271. PubMed ID: 38684048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.
    Hebbrecht K; Morrens M; Neels H; Roosens L; Sabbe BGC
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):999-1005. PubMed ID: 30141352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The 12-year trend report of antipsychotic usage in a nationwide claims database derived from four million people in Japan.
    Hata T; Kanazawa T; Hamada T; Nishihara M; Yoneda H; Nakajima M; Katsumata T
    J Psychiatr Res; 2020 Aug; 127():28-34. PubMed ID: 32450360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
    Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
    JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia.
    Cuomo A; Aguglia E; Biagini S; Carano A; Clerici M; D'Agostino A; De Filippis S; De Giorgi S; Goracci A; Libri C; Lombardi F; Lupi M; Maina G; Martinotti G; Nigro P; Pettorruso M; Ricci V; Rossi E; Russo F; Fagiolini A;
    J Clin Psychopharmacol; 2023 Jan-Feb 01; 43(1):35-38. PubMed ID: 36584247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
    Aggarwal A; Gopalakrishna G; Lauriello J
    Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study.
    Sanchez-Gistau V; Moreno MJ; Gómez-Lus S; Sicras-Mainar A; Crespo-Facorro B
    Front Psychiatry; 2023; 14():1207307. PubMed ID: 37599866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.